公开(公告)号：US20230045612A1

公开(公告)日：2023-02-09

申请号：US17847811

申请日：2022-06-23

Applicant: Tempest Therapeutics, Inc.

Inventor： Yalda BRAVO ,  Austin Chih-Yu CHEN ,  Jinyue DING ,  Robert GOMEZ ,  Heather LAM ,  Joe Fred NAGAMIZO ,  Renata Marcella OBALLA ,  David Andrew POWELL ,  Tao SHENG

IPC: C07D401/10 ,  C07D209/42 ,  C07D405/12 ,  C07D471/04 ,  C07D403/10 ,  C07D417/10 ,  C07D231/56

Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.

公开(公告)号：US20210387985A1

公开(公告)日：2021-12-16

申请号：US17354010

申请日：2021-06-22

Applicant: Tempest Therapeutics, Inc.

Inventor： Yalda BRAVO ,  Jason David BURCH ,  Austin Chih-Yu CHEN ,  Joe Fred NAGAMIZO

IPC: C07D471/04 ,  C07D209/18 ,  C07D231/56 ,  A61P35/00 ,  C07D235/08

Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g. controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.

公开(公告)号：US20210024491A1

公开(公告)日：2021-01-28

申请号：US17070554

申请日：2020-10-14

Applicant: Tempest Therapeutics, Inc.

Inventor： Yalda BRAVO ,  Austin Chih-Yu CHEN ,  Jinyue DING ,  Robert GOMEZ ,  Heather LAM ,  Joe Fred NAGAMIZO ,  Renata Marcella OBALLA ,  David Andrew POWELL ,  Tao SHENG

IPC: C07D401/10 ,  C07D209/42 ,  C07D405/12 ,  C07D471/04 ,  C07D403/10 ,  C07D417/10 ,  C07D231/56

Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.

公开(公告)号：US20210008046A1

公开(公告)日：2021-01-14

申请号：US16605408

申请日：2018-04-17

Applicant: TEMPEST THERAPEUTICS, INC.

Inventor： Yalda BRAVO ,  Jason David BURCH ,  Austin Chih-Yu CHEN ,  Joe Fred NAGAMIZO

IPC: A61K31/437 ,  A61K39/395 ,  C07D209/08 ,  C07D471/04 ,  C07D231/56 ,  C07D235/06 ,  C07D403/12 ,  C07D413/10 ,  A61K31/404 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/41

Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.

公开(公告)号：US20190315712A1

公开(公告)日：2019-10-17

申请号：US16387294

申请日：2019-04-17

Applicant: Tempest Therapeutics, Inc.

Inventor： Yalda BRAVO ,  Austin Chih-Yu CHEN ,  Jinyue DING ,  Robert GOMEZ ,  Heather LAM ,  Joe Fred NAGAMIZO ,  Renata Marcella OBALLA ,  David Andrew POWELL ,  Tao SHENG

IPC: C07D401/10 ,  C07D209/42 ,  C07D405/12 ,  C07D231/56 ,  C07D403/10 ,  C07D417/10 ,  C07D471/04

Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.

公开(公告)号：US20240150316A1

公开(公告)日：2024-05-09

申请号：US18467022

申请日：2023-09-14

Applicant: Tempest Therapeutics, Inc.

Inventor： Yalda BRAVO ,  Austin Chih-Yu CHEN ,  Jinyue DING ,  Robert GOMEZ ,  Heather LAM ,  Joe Fred NAGAMIZO ,  Renata Marcella OBALLA ,  David Andrew POWELL ,  Tao SHENG

IPC: C07D401/10 ,  C07D209/42 ,  C07D231/56 ,  C07D403/10 ,  C07D405/12 ,  C07D417/10 ,  C07D471/04

CPC classification number: C07D401/10 ,  C07D209/42 ,  C07D231/56 ,  C07D403/10 ,  C07D405/12 ,  C07D417/10 ,  C07D471/04

Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.

公开(公告)号：US20200283438A1

公开(公告)日：2020-09-10

申请号：US16880756

申请日：2020-05-21

Applicant: Tempest Therapeutics, Inc.

Inventor： Yalda BRAVO ,  Jason David BURCH ,  Austin Chih-Yu CHEN ,  Joe Fred NAGAMIZO

IPC: C07D471/04 ,  C07D209/18 ,  C07D231/56 ,  C07D235/08 ,  A61P35/00

Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.